Imfinzi® (durvalumab) – New indication
March 31, 2025 - AstraZeneca announced the FDA approval of Imfinzi (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
Top